| ²é¿´: 887 | »Ø¸´: 2 | |||
| ¡¾ÐüÉͽð±Ò¡¿»Ø´ð±¾ÌûÎÊÌ⣬×÷Õßwfpzmd360073½«ÔùËÍÄú 30 ¸ö½ð±Ò | |||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||
wfpzmd360073½ð³æ (СÓÐÃûÆø)
|
[ÇóÖú]
ÎÄÏ×ÇóÖú£¬¼±¼±¼±£¡£¡£¡£¡ ÒÑÓÐ1È˲ÎÓë
|
||
|
ÇóÖúһƪÁÙ´²Ñо¿ÎÄÕ£¬Â·¹ýµÄ´óÉñÇë°ï棬лл£¡£¡£¡£¡ Á´½Ó£ºhttps://pubmed.ncbi.nlm.nih.gov/38823410/ doi: 10.1016/S1470-2045(24)00159-1. Epub 2024 May 29 ÌâÄ¿£ºBL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study |
» ²ÂÄãϲ»¶
²©µ¼ÍƼö
ÒѾÓÐ2È˻ظ´
ÄÄÀï×ö¸Ê°±ËáÊÜÌåÓëÅäÌå½áºÏÂʵÄÊÔÑé
ÒѾÓÐ0È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ90È˻ظ´
¹ãÎ÷Ò½¿Æ´óѧ»ù´¡Ò½Ñ§Ôº×ÔÉíÃâÒß²¡¿ÎÌâ×éÕÐÊÕ»ù´¡Ò½Ñ§¡¢Ò©Ñ§ºÍÉúÎïѧµÈרҵµÄÑо¿Éú
ÒѾÓÐ7È˻ظ´
[ѧϰ×ÊÁÏ·ÖÏí] FAERSÊý¾Ý¿âµÄ²»Á¼·´Ó¦ÍÚ¾ò(ƵÊý·¨/±´Ò¶Ë¹·¨)
ÒѾÓÐ1È˻ظ´
ÕÐÊÕҽѧ¡¢»ù´¡Ò½Ñ§Ààµ÷¼ÁÑо¿Éú
ÒѾÓÐ0È˻ظ´
ÊÇ·ñÊôÓÚÆ¢ÉöÑôÐéÖ¤
ÒѾÓÐ0È˻ظ´
¹ØÓÚSCIÔÓÖ¾·¢±í¹ÒÃû
ÒѾÓÐ32È˻ظ´
¹ãÎ÷Ò½¿Æ´óѧ»ù´¡Ò½Ñ§Ôº×ÔÉíÃâÒß²¡¿ÎÌâ×éÕÐÊÕ»ù´¡Ò½Ñ§Ïà¹Ø×¨ÒµµÄµ÷¼ÁÑо¿Éú
ÒѾÓÐ2È˻ظ´

tfang
ľ³æÖ®Íõ (ÎÄ̳¾«Ó¢)
ľ³æ008Ö®´óÀÁ³æ
- Ó¦Öú: 109 (¸ßÖÐÉú)
- ¹ó±ö: 0.002
- ½ð±Ò: 119432
- É¢½ð: 8512
- ºì»¨: 147
- ɳ·¢: 3
- Ìû×Ó: 46142
- ÔÚÏß: 2068.3Сʱ
- ³æºÅ: 529162
- ×¢²á: 2008-03-20
- ÐÔ±ð: GG
- רҵ: ÂÌÉ«Óлú»¯Ñ§
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
|
ͨ¹ýÍøÅÌ·ÖÏíµÄÎļþ£ºBL-B01D1, a first-in-class EGFR¨CHER3 bispecific antibody¨Cdrug conjugate, in patients with locally advanced or metastatic solid tumours a first-in-human, open-label, multicentre, phase 1 study._20251127_083531.pdf Á´½Ó: https://pan.baidu.com/s/1Fjp97hdJLNbLM_NIE6nOHQ?pwd=bpib ÌáÈ¡Âë: bpib ¸´ÖÆÕâ¶ÎÄÚÈݺó´ò¿ª°Ù¶ÈÍøÅÌÊÖ»úApp£¬²Ù×÷¸ü·½±ãŶ |

3Â¥2025-11-27 08:35:43
zyqchem
ľ³æÖ®Íõ (ÎÄѧ̩¶·)
- Ó¦Öú: 158 (¸ßÖÐÉú)
- ½ð±Ò: 284345
- ºì»¨: 552
- ɳ·¢: 1960
- Ìû×Ó: 55006
- ÔÚÏß: 11822.1Сʱ
- ³æºÅ: 3786654
- ×¢²á: 2015-04-04
- רҵ: ºÏ³ÉÒ©Îﻯѧ
2Â¥2025-11-26 12:01:26













»Ø¸´´ËÂ¥